BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 27500812)

  • 1. Role of Dual-Hormone Closed-Loop Delivery System in the Future.
    Bally L; Thabit H; Hovorka R
    Diabetes Technol Ther; 2016 Aug; 18(8):452-4. PubMed ID: 27500812
    [No Abstract]   [Full Text] [Related]  

  • 2. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps.
    Pickup JC
    Diabetes Technol Ther; 2011 Jul; 13(7):695-8. PubMed ID: 21668344
    [No Abstract]   [Full Text] [Related]  

  • 3. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of Predictive Low-Glucose Management System in Hybrid of Full Closed Loop System.
    Choudhary P
    Diabetes Technol Ther; 2016 Jul; 18(7):408-9. PubMed ID: 27379979
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
    Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
    Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Advisory Panel Votes to Recommend Non-Adjunctive Use of Dexcom G5 Mobile CGM.
    Diabetes Technol Ther; 2016 Aug; 18(8):512-6. PubMed ID: 27472488
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Devices in Insulin Delivery.
    Meneghini LF; McNulty JN
    Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of using real-time sensor glucose values for treatment decisions in adolescents with poorly controlled type 1 diabetes mellitus: a pilot study.
    Fox LA; Balkman E; Englert K; Hossain J; Mauras N
    Pediatr Diabetes; 2017 Jun; 18(4):271-276. PubMed ID: 27435145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin Pumps.
    Pickup JC
    Diabetes Technol Ther; 2017 Feb; 19(S1):S19-S26. PubMed ID: 28192024
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
    Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
    Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin Infusion Sets and Continuous Glucose Monitoring Sensors: Where the Artificial Pancreas Meets the Patient.
    Forlenza GP
    Diabetes Technol Ther; 2017 Apr; 19(4):206-208. PubMed ID: 28418732
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline.
    Peters AL; Ahmann AJ; Battelino T; Evert A; Hirsch IB; Murad MH; Winter WE; Wolpert H
    J Clin Endocrinol Metab; 2016 Nov; 101(11):3922-3937. PubMed ID: 27588440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes.
    Danne T; Bangstad HJ; Deeb L; Jarosz-Chobot P; Mungaie L; Saboo B; Urakami T; Battelino T; Hanas R;
    Pediatr Diabetes; 2014 Sep; 15 Suppl 20():115-34. PubMed ID: 25182312
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Insulin-Induced Hypoglycemia in Type 1 Diabetes with Predictive Low Glucose Management System.
    Abraham MB; de Bock M; Paramalingam N; O'Grady MJ; Ly TT; George C; Roy A; Spital G; Karula S; Heels K; Gebert R; Fairchild JM; King BR; Ambler GR; Cameron F; Davis EA; Jones TW
    Diabetes Technol Ther; 2016 Jul; 18(7):436-43. PubMed ID: 27148807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Hypoglycemia Before Landing in a Patient with Type 1 Diabetes Using Sensor-Augmented Pump Therapy.
    Viñals C; Pané A; Quirós C; Giménez M; Conget I
    Diabetes Technol Ther; 2017 Aug; 19(8):491-492. PubMed ID: 28594566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.